

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the treatment of venous... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-985/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-985" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants.">
            <meta name="og:description" content="Read the latest article version by Jeffrey I. Weitz, Iqbal H. Jaffer, James C. Fredenburgh, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12057">
            <meta name="article-id" content="11174">
            <meta name="dc.title" content="Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants">
            <meta name="dc.description" content="The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment.">
            <meta name="dc.subject" content="direct oral anticoagulants, DOACs, venous thromboembolism, VTE, anticoagulant">
            <meta name="dc.creator" content="Weitz, Jeffrey I.">
            <meta name="dc.creator" content="Jaffer, Iqbal H.">
            <meta name="dc.creator" content="Fredenburgh, James C.">
            <meta name="dc.date" content="2017/06/23">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11174.1">
            <meta name="dc.source" content="F1000Research 2017 6:985">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="direct oral anticoagulants">
            <meta name="prism.keyword" content=" DOACs">
            <meta name="prism.keyword" content=" venous thromboembolism">
            <meta name="prism.keyword" content=" VTE">
            <meta name="prism.keyword" content=" anticoagulant">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/06/23">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="985">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11174.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-985">
            <meta name="citation_title" content="Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants">
            <meta name="citation_abstract" content="The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment.">
            <meta name="citation_description" content="The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment.">
            <meta name="citation_keywords" content="direct oral anticoagulants, DOACs, venous thromboembolism, VTE, anticoagulant">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jeffrey I. Weitz">
            <meta name="citation_author_institution" content="Department of Medicine, McMaster University, Hamilton, Ontario, Canada">
            <meta name="citation_author_institution" content="Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada">
            <meta name="citation_author_institution" content="Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada">
            <meta name="citation_author" content="Iqbal H. Jaffer">
            <meta name="citation_author_institution" content="Department of Surgery, McMaster University, Hamilton, Ontario, Canada">
            <meta name="citation_author_institution" content="Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada">
            <meta name="citation_author" content="James C. Fredenburgh">
            <meta name="citation_author_institution" content="Department of Medicine, McMaster University, Hamilton, Ontario, Canada">
            <meta name="citation_author_institution" content="Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada">
            <meta name="citation_publication_date" content="2017/06/23">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="985">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11174.1">
            <meta name="citation_firstpage" content="985">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-985/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-985.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12057 /> <input type=hidden id=articleId name=articleId value=11174 /> <input type=hidden id=xmlUrl value="/articles/6-985/v1/xml"/> <input type=hidden id=xmlFileName value="-6-985-v1.xml"> <input type=hidden id=article_uuid value=ec5be32c-00a3-4c41-bb60-a40c293e04f9 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11174.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11174.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-985"
  },
  "headline": "Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants",
  "datePublished": "2017-06-23T10:34:42",
  "dateModified": "2017-06-23T10:34:42",
  "author": [
    {
      "@type": "Person",
      "name": "Jeffrey I. Weitz"
    },    {
      "@type": "Person",
      "name": "Iqbal H. Jaffer"
    },    {
      "@type": "Person",
      "name": "James C. Fredenburgh"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-985.html",
            "name": "Recent advances in the treatment of venous thromboembolism in the..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the treatment of venous thromboembolism in the... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12057 data-id=11174 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11174.1" data-recommended="" data-doi="10.12688/f1000research.11174.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-985/v1/pdf?article_uuid=ec5be32c-00a3-4c41-bb60-a40c293e04f9" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11174-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11174-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11174-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Weitz JI, Jaffer IH and Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):985 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11174.1" target=_blank>https://doi.org/10.12688/f1000research.11174.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11174-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11174 id=track-article-signin-11174 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11174?target=/articles/6-985.html">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12057 /> <input name=articleId type=hidden value=11174 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:weitzj@taari.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jeffrey I. Weitz</span></a><a href="https://orcid.org/0000-0002-1092-7550" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1092-7550</div><sup>1,3,4</sup>,&nbsp;</span><span class="">Iqbal H. Jaffer<sup>2,4</sup>,&nbsp;</span><span class="">James C. Fredenburgh<sup>1,4</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:weitzj@taari.ca" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Jeffrey I. Weitz</span></a><a href="http://orcid.org/0000-0002-1092-7550" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1092-7550</div><sup>1,3,4</sup>,&nbsp;</span><span class="">Iqbal H. Jaffer<sup>2,4</sup>,&nbsp;</span><span class="">James C. Fredenburgh<sup>1,4</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 23 Jun 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11174.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, McMaster University, Hamilton, Ontario, Canada<br/> <sup>2</sup> Department of Surgery, McMaster University, Hamilton, Ontario, Canada<br/> <sup>3</sup> Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada<br/> <sup>4</sup> Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=23589-23758></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=5264-23757></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The direct oral anticoagulants (DOACs) have now supplanted vitamin K antagonists (VKAs) for the treatment of venous thromboembolism (VTE). The DOACs include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. The DOACs are as effective for the prevention of recurrence as conventional VTE treatment, consisting of a parenteral anticoagulant followed by a VKA, and are associated with less bleeding. Because of these properties and the convenience of fixed dosing without the need for routine coagulation monitoring, guidelines now recommend DOACs over VKAs for VTE treatment in patients without active cancer. This paper examines the increasing role of the DOACs for VTE treatment. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> direct oral anticoagulants, DOACs, venous thromboembolism, VTE, anticoagulant </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Jeffrey I. Weitz (<a href="mailto:weitzj@taari.ca">weitzj@taari.ca</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Jeffrey I. Weitz </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Jeffrey Weitz has received research support from Canadian Institutes of Health Research, Heart and Stroke Foundation, Canadian Foundation for Innovation, and Boehringer Ingelheim and consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Bayer, Janssen Pharmaceuticals, Portola, IONIS Pharmaceuticals, and Merck. Iqbal Jaffer has received research support from Boehringer Ingelheim and consulting fees from CryoLife. James Fredenburgh declares that he has no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp;  2017 Weitz JI <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Weitz JI, Jaffer IH and Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):985 (<a href="https://doi.org/10.12688/f1000research.11174.1" target=_blank>https://doi.org/10.12688/f1000research.11174.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 23 Jun 2017, <b>6</b>(F1000 Faculty Rev):985 (<a href="https://doi.org/10.12688/f1000research.11174.1" target=_blank>https://doi.org/10.12688/f1000research.11174.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 23 Jun 2017, <b>6</b>(F1000 Faculty Rev):985 (<a href="https://doi.org/10.12688/f1000research.11174.1" target=_blank>https://doi.org/10.12688/f1000research.11174.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e201>Introduction</h2><p class="" id=d91397e204>Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common condition that occurs for the first time in about 1 in 1,000 persons each year, and the incidence rises with age<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. About two-thirds of patients with symptomatic VTE present with DVT, while the remainder manifest as PE<sup><a href="#ref-3">3</a></sup>. Up to 12% of patients with PE and 6% of those with DVT die within 30 days<sup><a href="#ref-4">4</a></sup>. Of those who survive, 2 to 4% of PE patients develop chronic thromboembolic pulmonary hypertension, which can be fatal, and from 20 to 50% of DVT patients develop post-thrombotic syndrome, a chronic disorder characterized by leg swelling and pain that can lead to venous ulcers in severe cases<sup><a href="#ref-5">5</a>,<a href="#ref-6">6</a></sup>. Therefore, VTE is a common disorder associated with significant morbidity and mortality.</p><p class="" id=d91397e229>Anticoagulation is the cornerstone of VTE treatment. The goals of therapy are to prevent thrombus extension or embolization, to prevent new thrombi from forming, and to reduce the risk of long-term complications. Conventional VTE treatment consists of a parenteral anticoagulant, usually low-molecular-weight heparin (LMWH), overlapped and followed by a vitamin K antagonist (VKA), such as warfarin. Although effective and safe, conventional therapy is problematic because LMWH requires daily subcutaneous injection, which is difficult for some patients, and warfarin requires frequent monitoring and dose adjustments to ensure that the international normalized ratio (INR) is therapeutic, which is cumbersome for patients and physicians and costly for healthcare systems.</p><p class="" id=d91397e232>The treatment of VTE has been revolutionized with the recent introduction of the direct oral anticoagulants (DOACs), which can be given in fixed doses without routine monitoring. Four DOACs are licensed for VTE treatment: dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. Their approvals were based on phase 3 trials demonstrating that the DOACs were as effective as conventional therapy but led to less bleeding. In patients without active cancer, DOACs are now favored over VKAs in official guidelines for the treatment of VTE because they are similarly effective, are safer, and provide the ease of fixed dosing without having to monitor coagulation<sup><a href="#ref-7">7</a></sup>. Focusing on the evolving use of the DOACs, in this paper we will (a) discuss the results of the phase 3 trials, (b) categorize VTE patients based on whether or not they are DOAC candidates, (c) demonstrate how to choose amongst the DOACs, (d) provide licensed dosing information for the DOACs, (e) review the optimal treatment duration for VTE, (f) describe the periprocedural management of the DOACs in patients needing surgery or intervention, and (g) evaluate the management of DOAC-associated bleeding.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e242>DOACs for the treatment of VTE</h2><p class="" id=d91397e245>The DOACs were compared with conventional anticoagulation therapy in 27,023 patients with acute VTE in six trials: RE-COVER and RE-COVER II (Efficacy and Safety of Dabigatran Compared to Warfarin for 6-month Treatment of Acute Symptomatic Venous Thromboembolism) with dabigatran<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>, EINSTEIN DVT (Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients with Acute Symptomatic Deep-Vein Thrombosis without Symptomatic Pulmonary Embolism) and PE (Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism) with rivaroxaban<sup><a href="#ref-10">10</a>,<a href="#ref-11">11</a></sup>, AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy) with apixaban<sup><a href="#ref-12">12</a></sup>, and HOKUSAI VTE (Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism) with edoxaban<sup><a href="#ref-13">13</a></sup>. The primary efficacy endpoint in these trials was recurrent VTE or VTE-related death, while the primary safety outcome was either major bleeding or the composite of major and clinically relevant non-major bleeding. In a pooled analysis<sup><a href="#ref-14">14</a></sup>, rates of recurrent VTE and VTE-related death were 2.0% with DOACs and 2.2% with conventional therapy (relative risk [RR] 0.90, 95% confidence interval [CI] 0.771.06). Compared with VKAs, the DOACs were associated with a 39% reduction in the risk of major bleeding (RR 0.61, 95% CI 0.450.83), a 63% reduction in intracranial bleeding (RR 0.37, 95% CI 0.210.68), and a 64% reduction in fatal bleeding (RR 0.36, 95% CI 0.150.84). In addition, clinically relevant non-major bleeding was reduced by 27% with the DOACs compared with VKAs (RR 0.73, 95% CI 0.580.93). Therefore, the DOACs demonstrate non-inferior efficacy compared with well-managed VKA therapy but are associated with significantly less bleeding<sup><a href="#ref-14">14</a></sup>.</p><p class="" id=d91397e279>Whereas dabigatran and edoxaban were started after a minimum 5-day course of parenteral anticoagulant therapy<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a>,<a href="#ref-13">13</a></sup>, rivaroxaban and apixaban were administered in all-oral regimens starting with higher doses for 21 days and 7 days, respectively<sup><a href="#ref-10">11</a><a href="#ref-12">12</a></sup>. When used in this all-oral fashion, both agents were non-inferior to conventional therapy and were associated with significantly less major bleeding. Therefore, the DOACs simplify VTE treatment and facilitate out-of-hospital management of most patients with DVT and many with PE, thereby reducing healthcare costs. With these advantages, it is not surprising that clinical guidelines now endorse DOACs as first-line VTE treatment<sup><a href="#ref-7">7</a></sup>.</p><p class="" id=d91397e303>Rivaroxaban, apixaban, and dabigatran were compared with placebo for extended treatment in VTE patients who completed at least 6 months of anticoagulation therapy in the EINSTEIN-extension (Once-daily Oral Rivaroxaban versus Placebo in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism)<sup><a href="#ref-11">11</a></sup>, AMPLIFY-EXT (Apixaban after the Initial Management of Pulmonary Embolism and Deep Vein Thrombosis with First-line Therapy-extended Treatment)<sup><a href="#ref-15">15</a></sup>, and RE-SONATE (Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism)<sup><a href="#ref-16">16</a></sup> trials, respectively. In addition, dabigatran was compared with warfarin for extended therapy in the RE-MEDY trial (Dabigatran or Warfarin for Extended Maintenance Therapy of Venous Thromboembolism)<sup><a href="#ref-16">16</a></sup>, and rivaroxaban was compared with aspirin in the EINSTEIN CHOICE trial (Reduced-dose Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism)<sup><a href="#ref-17">17</a><a href="#ref-19">19</a></sup>.</p><p class="" id=d91397e329>In the RE-MEDY study<sup><a href="#ref-16">16</a></sup>, dabigatran was non-inferior to warfarin for extended VTE treatment (hazard ratio [HR] 1.44, 95% CI 0.782.64) but was associated with a 46% reduction in major or clinically relevant non-major bleeding (HR 0.54, 95% CI 0.410.71). Pooled analyses of the three placebo-controlled trials revealed a significant reduction in the rate of recurrent VTE and VTE-related mortality with the DOACs but an increased rate of major and clinically relevant non-major bleeding<sup><a href="#ref-17">17</a>,<a href="#ref-20">20</a></sup>.</p><p class="" id=d91397e344>The AMPLIFY-EXT trial compared two dosing regimens of apixaban (2.5 mg and 5 mg twice daily) with placebo to identify the dose providing the best balance of efficacy and safety<sup><a href="#ref-15">15</a></sup>. The risks of recurrent VTE were similar with the lower- and higher-dose apixaban regimens (RR 0.97, 95% CI 0.462.02), and neither regimen was associated with a significant increase in major bleeding compared with placebo, but there was a trend for less non-major bleeding with the lower dose (RR 0.74, 95% CI 0.461.22).</p><p class="" id=d91397e351>Compared with placebo for extended VTE treatment, aspirin reduced the rate of recurrence by about 32% without a significant increase in major bleeding<sup><a href="#ref-18">18</a>,<a href="#ref-21">21</a></sup>. Based on this finding, guidelines now suggest aspirin for extended VTE treatment in patients who elect to stop anticoagulant therapy<sup><a href="#ref-7">7</a></sup>. The results of the EINSTEIN CHOICE trial challenge this suggestion<sup><a href="#ref-19">19</a></sup>. This trial compared two doses of rivaroxaban (20 mg and 10 mg once daily) with aspirin to identify the optimal dose of rivaroxaban for extended VTE treatment and to determine whether rivaroxaban is superior to aspirin for this purpose<sup><a href="#ref-18">18</a></sup>. The rates of recurrent VTE with the 20 mg and 10 mg rivaroxaban regimens were 1.5% and 1.2%, respectively, as compared with 4.4% in the aspirin group (HR 20 mg rivaroxaban versus aspirin 0.34, 95% CI 0.200.59 and HR 10 mg rivaroxaban versus aspirin 0.26, 95% CI 0.140.47; P&lt;0.001 for both comparisons). Rates of major bleeding were 0.5% in the 20 mg rivaroxaban group, 0.4% in the 10 mg rivaroxaban group, and 0.3% in the aspirin group, and the rates of clinically relevant non-major bleeding also were similar (2.7%, 2.0%, and 1.8%, respectively)<sup><a href="#ref-19">19</a></sup>. Therefore, both dose regimens of rivaroxaban are superior to aspirin for the prevention of recurrent VTE and are associated with similar rates of bleeding. These results suggest that there is little role for aspirin for extended VTE treatment except for those who cannot afford rivaroxaban or have contraindications to its use.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e380>Choosing the right anticoagulant for the right patient</h2><p class="" id=d91397e383>When faced with a patient with acute VTE, the first question to ask is whether the patient is suitable for DOAC treatment. Patients requiring thrombolytic therapy for high-risk PE associated with hypotension are usually started on heparin or LMWH but can be switched to a DOAC when their condition stabilizes. DOACs should be avoided in patients with renal impairment (creatinine clearance &lt;15 mL/minute for rivaroxaban, apixaban, and edoxaban and &lt;30 mL/minute for dabigatran), in those with severe hepatic impairment associated with coagulopathy, in those younger than 18 years of age, or in women who are pregnant or breastfeeding (<a href="#T1">Table 1</a>). VKAs remain the treatment of choice for VTE patients with a creatinine clearance &lt;15 mL/minute and for those with antiphospholipid syndrome associated with arterial thrombosis. Although the data with DOACs in patients with cancer-associated VTE are promising<sup><a href="#ref-14">14</a></sup>, few such patients were included in the randomized trials. Consequently, guidelines recommend LMWH as first-line therapy in patients with cancer-associated thrombosis<sup><a href="#ref-7">7</a>,<a href="#ref-22">22</a></sup>. However, ongoing trials are comparing DOACs with LMWH in such patients<sup><a href="#ref-23">23</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Patients with venous thromboembolism who are not candidates for direct oral anticoagulants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e415 class=n-a></a><tbody><a name=d91397e417 class=n-a></a><tr><a name=d91397e419 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e421 class=n-a></a>Planned thrombolysis or intervention</td></tr><tr><a name=d91397e425 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e427 class=n-a></a>Severe renal impairment (creatinine clearance less than<br class=br>15 mL/minute)</td></tr><tr><a name=d91397e433 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e435 class=n-a></a>Hepatic impairment with coagulopathy</td></tr><tr><a name=d91397e439 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e441 class=n-a></a>Pregnant or breastfeeding</td></tr><tr><a name=d91397e445 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e447 class=n-a></a>Younger than 18 years of age</td></tr><tr><a name=d91397e452 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e454 class=n-a></a>Antiphospholipid syndrome with history of arterial thrombosis</td></tr></tbody></table></div><p class="" id=d91397e461>DOACs should probably not be used in those with a body weight over 120 kg because data on their efficacy in such patients are lacking<sup><a href="#ref-24">24</a></sup>. Patients who cannot afford DOACs should receive conventional anticoagulant treatment because VKAs are less expensive. Finally, if compliance is a concern, or if the patient is taking multiple medications that may interact with the DOACs (including strong inhibitors of P-glycoprotein such as quinidine, verapamil, or dronedarone, or potent inducers or inhibitors of both P-glycoprotein and cytochrome P450 A34 isoenzymes such as carbamazepine, phenytoin, rifampin, St Johns wort, itraconazole, or ketoconazole), VKAs may be a better choice because INR monitoring will ensure therapeutic dosing.</p><p class="" id=d91397e468>In patients already taking VKAs and whose INR is erratic, VTE treatment should be replaced with a DOAC. This can also be considered in those for whom INR testing and dose adjustment is onerous, such as those with limited mobility. For long-term treatment, there is likely to be a lower risk of bleeding with the use of DOACs than with VKAs, particularly if the doses of apixaban or rivaroxaban are reduced to 2.5 mg twice daily and 10 mg once daily, respectively, after 6 months or more of full-dose treatment.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e474>Choosing amongst the DOACs</h2><p class="" id=d91397e477>In VTE patients eligible for DOACs, there is no evidence to recommend one agent over another because head-to-head comparisons are lacking. Nonetheless, guidance can be provided (<a href="#T2">Table 2</a>). Creatinine clearance rates provide an essential metric in the decision-making process. For patients with creatinine clearance rates between 15 and 30 mL/minute, dabigatran should be avoided and an oral factor Xa inhibitor is suggested because they exhibit a lower dependence on renal excretion. To streamline transitions of care, rivaroxaban and apixaban should be considered because they have been evaluated in all-oral regimens, an approach that facilitates transitions from the clinic or the emergency department to home. Choice between the two depends on the ability to switch from the higher initial dose to the maintenance dose at 3 weeks or 1 week, respectively, and subsequently on patient preference for once- or twice-daily dosing regimens. In contrast, dabigatran and edoxaban were not evaluated as all-oral regimens and should be prescribed only after patients have completed a minimum 5-day course of treatment with LMWH or heparin. For patients over the age of 75 years with moderate renal impairment (creatinine clearance between 15 and 50 mL/minute) and low body weight, oral factor Xa inhibitors may be good choices because their benefit-to-risk profiles in such patients are superior to those of conventional therapy<sup><a href="#ref-12">12</a>,<a href="#ref-25">25</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T2 class=n-a></a><div class=caption><h3>Table 2. Choosing amongst the direct oral anticoagulants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e501 class=n-a></a><thead><a name=d91397e503 class=n-a></a><tr><a name=d91397e505 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d91397e507 class=n-a></a>Characteristics</th><th align=center colspan=1 rowspan=1 valign=top><a name=d91397e510 class=n-a></a>Drug Choice</th><th align=center colspan=1 rowspan=1 valign=top><a name=d91397e513 class=n-a></a>Rationale</th></tr></thead><tbody><a name=d91397e518 class=n-a></a><tr><a name=d91397e520 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e522 class=n-a></a><b>CrCl 1530 mL/minute</b></td><td align=left colspan=1 rowspan=1><a name=d91397e526 class=n-a></a>Rivaroxaban, apixaban,<br class=br>or edoxaban</td><td align=left colspan=1 rowspan=1><a name=d91397e531 class=n-a></a>Less affected by renal impairment than<br class=br>dabigatran</td></tr><tr><a name=d91397e537 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e539 class=n-a></a><b>All-oral therapy</b></td><td align=left colspan=1 rowspan=1><a name=d91397e543 class=n-a></a>Rivaroxaban or apixaban</td><td align=left colspan=1 rowspan=1><a name=d91397e546 class=n-a></a>Dabigatran and edoxaban require heparin<br class=br>bridging</td></tr><tr><a name=d91397e552 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e554 class=n-a></a><b>Dyspepsia or upper GI</b><br class=br><b>complaints</b></td><td align=left colspan=1 rowspan=1><a name=d91397e561 class=n-a></a>Rivaroxaban, apixaban,<br class=br>or edoxaban</td><td align=left colspan=1 rowspan=1><a name=d91397e566 class=n-a></a>Dyspepsia with dabigatran in up to 10% of<br class=br>patients</td></tr><tr><a name=d91397e572 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e574 class=n-a></a><b>Recent GI bleed</b></td><td align=left colspan=1 rowspan=1><a name=d91397e578 class=n-a></a>Apixaban or low-dose<br class=br>edoxaban</td><td align=left colspan=1 rowspan=1><a name=d91397e583 class=n-a></a>More GI bleeding with rivaroxaban and high-dose<br class=br>dabigatran or edoxaban than with warfarin</td></tr><tr><a name=d91397e589 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e591 class=n-a></a><b>Significant CAD</b></td><td align=left colspan=1 rowspan=1><a name=d91397e595 class=n-a></a>Rivaroxaban, apixaban,<br class=br>or edoxaban</td><td align=left colspan=1 rowspan=1><a name=d91397e600 class=n-a></a>Possible small MI signal with dabigatran </td></tr><tr><a name=d91397e605 class=n-a></a><td align=left colspan=1 rowspan=1><a name=d91397e607 class=n-a></a><b>Poor compliance with</b><br class=br><b>twice-daily dosing</b></td><td align=left colspan=1 rowspan=1><a name=d91397e614 class=n-a></a>Rivaroxaban or edoxaban</td><td align=left colspan=1 rowspan=1><a name=d91397e617 class=n-a></a>Only agents given once-daily</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d91397e625 class=n-a></a><p id=d91397e627> CAD, coronary artery disease; CrCl, creatinine clearance; GI, gastrointestinal; MI, myocardial infarction</p></div></div></div><p class="" id=d91397e633>It may be prudent to avoid dabigatran in patients with coronary artery disease because even though the rate of acute coronary syndrome with a 6-month course of dabigatran was similar to that with warfarin in RE-COVER and RE-COVER II (0.3% and 0.2%, respectively)<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>, the rate of acute coronary syndrome was higher with dabigatran than with warfarin in the RE-MEDY trial (0.9% and 0.2%, respectively; P=0.02), which compared them for extended VTE treatment for over a year<sup><a href="#ref-16">16</a></sup>. The rate of myocardial infarction also was higher with dabigatran than with warfarin in the RE-LY trial (Randomized Evaluation of Long-term Anticoagulation with Dabigatran Etexilate)<sup><a href="#ref-26">26</a></sup>. Although on re-analysis the difference was not statistically significant<sup><a href="#ref-27">27</a></sup>, meta-analyses suggest that the risk of myocardial infarction is higher with dabigatran than it is with warfarin<sup><a href="#ref-28">28</a></sup>. It is likely that the decreased bleeding with dabigatran compared with warfarin observed in RE-CORD, RE-CORD II, and RE-MEDY outweighs any small increase in acute coronary events; however, the oral factor Xa inhibitors offer the same safety advantage over warfarin and, in contrast to dabigatran, have not been associated with an increased risk of acute coronary syndrome. Therefore, with the uncertainty surrounding the increased risk of acute coronary syndrome with dabigatran compared with warfarin, an oral factor Xa inhibitor may be a better choice in patients with coronary artery disease.</p><p class="" id=d91397e659>Dabigatran also may not be the best choice for patients with upper gastrointestinal complaints because dyspepsia occurs in up to 10% of cases, although this tends to subside over time and often resolves when the drug is taken with food.</p><p class="" id=d91397e663>Although the risk of gastrointestinal bleeding was higher with the full-dose DOAC regimens than with warfarin in the phase 3 trials in patients with atrial fibrillation<sup><a href="#ref-29">29</a></sup>, this does not appear to be the case in VTE patients, probably because they are younger than those with atrial fibrillation, take fewer medications, and have fewer comorbidities. Thus, in a pooled analysis of the phase 3 VTE treatment trials, there was a non-significant trend for less bleeding with the DOACs than with VKAs (RR 0.77, 95% CI 0.491.21; p=0.11)<sup><a href="#ref-30">30</a></sup>.</p><p class="" id=d91397e674>The risk of bleeding with DOACs is increased with concomitant use of antiplatelet agents, such as aspirin and non-steroidal anti-inflammatory drugs, and these agents should be avoided if possible. For patients who must use aspirin, the daily dose of aspirin should not exceed 100 mg.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e680>Choosing the right dose of DOACs</h2><p class="" id=d91397e683>To maximize efficacy, it is critical that the DOACs be used in the right dose. Depending on the agent, regulators have provided clinicians with dosing recommendations defined by characteristics including advanced age, reduced renal function, low body weight, and concomitant administration of potent P-glycoprotein inhibitors, factors associated with increased drug exposure and increased bleeding risk (<a href="#T3">Table 3</a>). Despite clear dosing recommendations, however, observational data suggest that the lower doses of the DOACs are over prescribed, potentially compromising the efficacy of DOACs in clinical practice<sup><a href="#ref-31">31</a></sup>. Education is needed to reverse this trend.</p><div class="table-wrap panel clearfix"><a name=T3 class=n-a></a><div class=caption><h3>Table 3. Licensed direct oral anticoagulant dosing regimens for the treatment of venous thromboembolism.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e704 class=n-a></a><thead><a name=d91397e706 class=n-a></a><tr><a name=d91397e708 class=n-a></a><th colspan=1 rowspan=1><a name=d91397e710 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d91397e712 class=n-a></a>Dabigatran</th><th align=center colspan=1 rowspan=1><a name=d91397e715 class=n-a></a>Rivaroxaban</th><th align=center colspan=1 rowspan=1><a name=d91397e718 class=n-a></a>Apixaban</th><th align=center colspan=1 rowspan=1><a name=d91397e721 class=n-a></a>Edoxaban</th></tr></thead><tbody><a name=d91397e726 class=n-a></a><tr><a name=d91397e728 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e730 class=n-a></a>Initial</td><td align=center colspan=1 rowspan=1><a name=d91397e733 class=n-a></a>After LMWH for at least<br class=br>5 days, 150 mg BID</td><td align=center colspan=1 rowspan=1><a name=d91397e738 class=n-a></a>15 mg BID for<br class=br>21 days</td><td align=center colspan=1 rowspan=1><a name=d91397e743 class=n-a></a>10 mg BID<br class=br>for 7 days</td><td align=center colspan=1 rowspan=1><a name=d91397e748 class=n-a></a>After LMWH for at least<br class=br>5 days, 60 mg OD</td></tr><tr><a name=d91397e754 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e756 class=n-a></a>Renal<br class=br>Adjustment</td><td align=center colspan=1 rowspan=1><a name=d91397e761 class=n-a></a>110 mg BID if  80 years,<br class=br>moderate renal impairment,<br class=br>or at risk for bleeding</td><td align=center colspan=1 rowspan=1><a name=d91397e768 class=n-a></a>N/A</td><td align=center colspan=1 rowspan=1><a name=d91397e771 class=n-a></a>N/A</td><td align=center colspan=1 rowspan=1><a name=d91397e774 class=n-a></a>30 mg OD if CrCl<br class=br>1550 mL/minute, weight<br class=br>&lt;60 kg, or potent P-gp<br class=br>inhibitors</td></tr><tr><a name=d91397e784 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e786 class=n-a></a>Long Term</td><td align=center colspan=1 rowspan=1><a name=d91397e789 class=n-a></a>150 or 110 mg BID</td><td align=center colspan=1 rowspan=1><a name=d91397e792 class=n-a></a>20 mg OD</td><td align=center colspan=1 rowspan=1><a name=d91397e795 class=n-a></a>5 mg BID</td><td align=center colspan=1 rowspan=1><a name=d91397e798 class=n-a></a>60 or 30 mg OD</td></tr><tr><a name=d91397e802 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e804 class=n-a></a>Extended</td><td align=center colspan=1 rowspan=1><a name=d91397e807 class=n-a></a>Same dose</td><td align=center colspan=1 rowspan=1><a name=d91397e810 class=n-a></a>20 or 10 mg OD</td><td align=center colspan=1 rowspan=1><a name=d91397e813 class=n-a></a>2.5 mg BID</td><td align=center colspan=1 rowspan=1><a name=d91397e816 class=n-a></a>Same dose</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d91397e824 class=n-a></a><p id=d91397e826> BID, twice daily; CrCl, creatinine clearance; LMWH, low molecular weight heparin; N/A, not applicable; OD, once daily; P-gp, P-glycoprotein</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e836>Optimal duration of VTE treatment</h2><p class="" id=d91397e839>Optimizing the duration of anticoagulant therapy for VTE is important to minimize the risk of bleeding. All VTE patients require a minimum of 3 months of anticoagulant treatment. For patients with VTE provoked by a transient and reversible risk factor such as surgery, 3 months of anticoagulation is usually sufficient<sup><a href="#ref-7">7</a></sup>. In contrast, patients with ongoing risk factors, such as active cancer, or those with unprovoked VTE are often given extended anticoagulation therapy because their risk of recurrence is high if treatment is stopped<sup><a href="#ref-7">7</a></sup>. Therefore, many VTE patients require long-term anticoagulation therapy.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e853>Periprocedural management in patients receiving DOACs</h2><p class="" id=d91397e856>Patients receiving long-term anticoagulant therapy often require elective surgery or invasive procedures, and appropriate perioperative management is important. To reduce the risk of bleeding complications, DOACs should be withheld for at least 24 hours before procedures associated with a moderate risk of bleeding and for at least 48 hours before procedures associated with a high risk of bleeding or if spinal anesthesia is planned<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d91397e863>Assessment of the anticoagulant effect of the DOACs or quantification of plasma drug levels can help guide the timing of surgery (<a href="#T4">Table 4</a>). These assessments depend on knowing which DOAC the patient is taking, the timing of intake of the last dose, and the impact of renal function on the half-life of the drug. Unfortunately, drug-specific tests are not widely or rapidly available. Regulators and hospitals need to work together to address this gap.</p><div class="table-wrap panel clearfix"><a name=T4 class=n-a></a><div class=caption><h3>Table 4. Assays to measure the anticoagulant activity or plasma levels of the direct oral anticoagulants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e880 class=n-a></a><thead><a name=d91397e882 class=n-a></a><tr><a name=d91397e884 class=n-a></a><th colspan=1 rowspan=1><a name=d91397e886 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d91397e888 class=n-a></a>Dabigatran</th><th align=center colspan=1 rowspan=1><a name=d91397e891 class=n-a></a>Rivaroxaban</th><th align=center colspan=1 rowspan=1><a name=d91397e894 class=n-a></a>Apixaban</th><th align=center colspan=1 rowspan=1><a name=d91397e897 class=n-a></a>Edoxaban</th></tr></thead><tbody><a name=d91397e902 class=n-a></a><tr><a name=d91397e904 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e906 class=n-a></a> <b>PT</b> </td><td align=center colspan=1 rowspan=1><a name=d91397e912 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e915 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e918 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e921 class=n-a></a></td></tr><tr><a name=d91397e925 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e927 class=n-a></a> <b>aPTT</b> </td><td align=center colspan=1 rowspan=1><a name=d91397e933 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e936 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e939 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e942 class=n-a></a></td></tr><tr><a name=d91397e946 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e948 class=n-a></a> <b>dTT</b> </td><td align=center colspan=1 rowspan=1><a name=d91397e954 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e957 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e960 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e963 class=n-a></a></td></tr><tr><a name=d91397e967 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e969 class=n-a></a> <b>ECT</b> </td><td align=center colspan=1 rowspan=1><a name=d91397e975 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e978 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e981 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e984 class=n-a></a></td></tr><tr><a name=d91397e988 class=n-a></a><td align=center colspan=1 rowspan=1><a name=d91397e990 class=n-a></a> <b>Anti-FXa</b><br class=br><b>Assays</b> </td><td align=center colspan=1 rowspan=1><a name=d91397e999 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e1002 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e1005 class=n-a></a></td><td align=center colspan=1 rowspan=1><a name=d91397e1008 class=n-a></a></td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d91397e1016 class=n-a></a><p id=d91397e1018> aPTT, activated partial thromboplastin time; dTT, diluted thrombin time; ECT, ecarin clotting time; FXa, factor Xa; PT, prothrombin time</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e1027>Bleeding management in patients receiving DOACs</h2><p class="" id=d91397e1030>Managing bleeding with DOACs is done in a comparable manner to that with VKAs. When assessing a bleeding event, one must first determine how severe it is (i.e. mild, moderate-to-severe, or life-threatening) and where it is occurring (critical or non-critical site). Local measures can typically be employed to manage mild bleeding (e.g. epistaxis), but, in the case of persistent bleeds, it may be necessary to postpone the patients subsequent dose or to suspend treatment temporarily<sup><a href="#ref-33">33</a></sup>. Because DOACs have short half-lives, discontinuing their use normally results in rapid normalization of coagulation tests, as long as renal function is normal. The decision to briefly or permanently halt anticoagulation should always be taken with a view to balance the risk of bleeding against the risk of thrombosis.</p><p class="" id=d91397e1037>In patients with moderate-to-severe bleeding events, supportive therapy is the mainstay of management<sup><a href="#ref-33">33</a></sup>. Because of the short half-life of the DOACs, most cases of bleeding will resolve within 12 hours provided that renal function is not severely compromised. The DOAC should be temporarily stopped as should concomitant long-acting antiplatelet agents (e.g. clopidogrel, ticagrelor, or prasugrel) if possible. Renal function should be assessed by measuring the serum creatinine and calculating the creatinine clearance. The anticoagulant effects or plasma levels of the DOACs can be determined using commercially available and validated assays<sup><a href="#ref-34">34</a></sup> to assess the contribution of the DOAC to the bleeding event.</p><p class="" id=d91397e1048>Routine supportive measures include hemodynamic support with fluid replacement and administration of blood products, such as packed red blood cells, fresh-frozen plasma, and platelets if the patient has thrombocytopenia or if they were on long-acting antiplatelet agents (<a href="#f1">Figure 1</a>). The source of bleeding should be identified and, if possible, mechanical or surgical measures should be used to stop the bleeding; tranexamic acid can be considered. In the event of a DOAC overdose, gastric lavage and activated charcoal can be used within 24 hours of ingestion. An important aspect of bleeding management is to determine when reversal of the DOAC is indicated<sup><a href="#ref-35">35</a></sup>.</p><div class="fig panel clearfix"><a name=f1 class=n-a></a><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/12057/fcba49ae-c2c1-4ec4-8979-4b36d1c05ac0_figure1.gif"><img alt="fcba49ae-c2c1-4ec4-8979-4b36d1c05ac0_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/12057/fcba49ae-c2c1-4ec4-8979-4b36d1c05ac0_figure1.gif"></a><div class=caption><h3>Figure 1. Management of direct oral anticoagulant-associated bleeding.</h3><p id=d91397e1068>With minor bleeding, local measures and delaying or holding 12 doses is sufficient. With moderate to severe bleeding, the direct oral anticoagulant should be held, and supportive therapy should be administered. For life-threatening bleeding, reversal should be undertaken.</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e1078>Indications for DOAC reversal</h2><p class="" id=d91397e1081>The reversal of DOACs should be considered with life-threatening bleeding, such as intracranial hemorrhage, bleeding into a critical organ (e.g. intraocular bleeding) or a closed space (e.g. pericardial or retroperitoneal bleeding), ongoing bleeding despite supportive measures, and, particularly with dabigatran-associated bleeding, if there is associated acute kidney injury where a long delay in drug clearance is expected (<a href="#T5">Table 5</a>). Reversal should also be considered in patients who require urgent surgery or interventions that are associated with a high risk of bleeding and that cannot be delayed for at least 8 to 12 hours to allow the DOACs to clear from the circulation<sup><a href="#ref-35">35</a></sup>.</p><div class="table-wrap panel clearfix"><a name=T5 class=n-a></a><div class=caption><h3>Table 5. Indications for reversal of direct oral anticoagulants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e1102 class=n-a></a><tbody><a name=d91397e1104 class=n-a></a><tr><a name=d91397e1106 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1107 class=n-a></a>Need for urgent surgery or intervention that cannot be delayed for at least 8 hours</td></tr><tr><a name=d91397e1110 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1111 class=n-a></a>Life-threatening bleeding (e.g. intracranial bleed)</td></tr><tr><a name=d91397e1114 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1115 class=n-a></a>Bleeding into a critical organ (e.g. intraocular bleed) or closed space (e.g. pericardial or<br class=br>retroperitoneal bleed)</td></tr><tr><a name=d91397e1120 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1121 class=n-a></a>Ongoing bleeding despite supportive measures</td></tr><tr><a name=d91397e1124 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1125 class=n-a></a>Expected long delay in restoration of hemostasis (e.g. over-anticoagulation with<br class=br>dabigatran in the setting of acute kidney injury)</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e1136>Reversal agents for the DOACs</h2><p class="" id=d91397e1139>Specific reversal agents include idarucizumab, which reverses only dabigatran, andexanet alfa, which reverses rivaroxaban, apixaban, edoxaban, and heparin, and ciraparantag, which reverses all of the DOACs and heparin (<a href="#T6">Table 6</a>). Of these, only idarucizumab is licensed and widely available; andexanet is under regulatory consideration, and ciraparantag has not yet been evaluated in patients. Until specific reversal agents for the oral factor Xa inhibitors are available, prothrombin complex concentrate should be considered.</p><div class="table-wrap panel clearfix"><a name=T6 class=n-a></a><div class=caption><h3>Table 6. Features of specific reversal agents for the direct oral anticoagulants.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d91397e1156 class=n-a></a><thead><a name=d91397e1158 class=n-a></a><tr><a name=d91397e1160 class=n-a></a><th colspan=1 rowspan=1><a name=d91397e1162 class=n-a></a></th><th align=center colspan=1 rowspan=1><a name=d91397e1164 class=n-a></a>Idarucizumab</th><th align=center colspan=1 rowspan=1><a name=d91397e1167 class=n-a></a>Andexanet-alfa</th><th align=center colspan=1 rowspan=1><a name=d91397e1170 class=n-a></a>Ciraparantag</th></tr></thead><tbody><a name=d91397e1175 class=n-a></a><tr><a name=d91397e1177 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1178 class=n-a></a><b>Structure</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1182 class=n-a></a>Recombinant humanized<br class=br>Fab fragment</td><td align=center colspan=1 rowspan=1><a name=d91397e1187 class=n-a></a>Recombinant human factor Xa<br class=br>variant</td><td align=center colspan=1 rowspan=1><a name=d91397e1192 class=n-a></a>Synthetic small molecule</td></tr><tr><a name=d91397e1195 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1196 class=n-a></a><b>Molecular mass (Da)</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1200 class=n-a></a>48,000</td><td align=center colspan=1 rowspan=1><a name=d91397e1203 class=n-a></a>39,000</td><td align=center colspan=1 rowspan=1><a name=d91397e1206 class=n-a></a>513</td></tr><tr><a name=d91397e1209 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1210 class=n-a></a><b>Synthesis</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1214 class=n-a></a>Expressed in Chinese<br class=br>hamster ovary cells</td><td align=center colspan=1 rowspan=1><a name=d91397e1219 class=n-a></a>Expressed in Chinese hamster<br class=br>ovary cells</td><td align=center colspan=1 rowspan=1><a name=d91397e1224 class=n-a></a>Chemical synthesis</td></tr><tr><a name=d91397e1227 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1228 class=n-a></a><b>Mechanism of action</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1232 class=n-a></a>Binds dabigatran with<br class=br>high affinity</td><td align=center colspan=1 rowspan=1><a name=d91397e1237 class=n-a></a>Competes with factor Xa for binding<br class=br>rivaroxaban, apixaban, or edoxaban</td><td align=center colspan=1 rowspan=1><a name=d91397e1242 class=n-a></a>Binds direct oral anticoagulants<br class=br>via hydrogen bond formation</td></tr><tr><a name=d91397e1247 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1248 class=n-a></a><b>Target</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1252 class=n-a></a>Dabigatran</td><td align=center colspan=1 rowspan=1><a name=d91397e1255 class=n-a></a>Rivaroxaban, apixaban, edoxaban,<br class=br>and heparin</td><td align=center colspan=1 rowspan=1><a name=d91397e1260 class=n-a></a>Dabigatran, rivaroxaban,<br class=br>apixaban, edoxaban, and heparin</td></tr><tr><a name=d91397e1266 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1267 class=n-a></a><b>Administration</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1271 class=n-a></a>Intravenous bolus</td><td align=center colspan=1 rowspan=1><a name=d91397e1274 class=n-a></a>Intravenous bolus followed by<br class=br>2-hour infusion</td><td align=center colspan=1 rowspan=1><a name=d91397e1279 class=n-a></a>Intravenous bolus</td></tr><tr><a name=d91397e1282 class=n-a></a><td colspan=1 rowspan=1><a name=d91397e1283 class=n-a></a><b>Cost</b></td><td align=center colspan=1 rowspan=1><a name=d91397e1287 class=n-a></a>$3,500 per dose in<br class=br>United States</td><td align=center colspan=1 rowspan=1><a name=d91397e1292 class=n-a></a>Unknown; likely to cost more than<br class=br>idarucizumab</td><td align=center colspan=1 rowspan=1><a name=d91397e1297 class=n-a></a>Unknown; likely to cost less than<br class=br>idarucizumab and andexanet</td></tr></tbody></table></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d91397e1308>Conclusions and future directions</h2><p class="" id=d91397e1311>The DOACs are at least as effective, safer, and more convenient than VKAs and have streamlined VTE treatment. Post-marketing studies suggest that the favorable results of clinical trials can readily be translated into practice. Nonetheless, to optimize safety, there remains a need for selection of the appropriate patient, drug, and dose as well as careful follow up.</p><p class="" id=d91397e1314>Although the DOACs represent a major advance in VTE treatment, gaps persist. For example, more information is needed about their utility in VTE patients with active cancer, their efficacy and safety in patients with a creatinine clearance between 15 and 30 mL/minute, and optimal dosing in obese and pediatric patients. Ongoing studies will help to address these gaps and enable DOAC use in a broader spectrum of VTE patients.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d91397e1 class=n-a></a><h2 class=main-title id=d91542>Competing interests</h2><p class=metadata-entry><a name=d91397e136 class=n-a></a><p id=d91397e138> Jeffrey Weitz has received research support from Canadian Institutes of Health Research, Heart and Stroke Foundation, Canadian Foundation for Innovation, and Boehringer Ingelheim and consulting fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Bayer, Janssen Pharmaceuticals, Portola, IONIS Pharmaceuticals, and Merck. Iqbal Jaffer has received research support from Boehringer Ingelheim and consulting fees from CryoLife. James Fredenburgh declares that he has no competing interests.</p></p></div><div class=back-section><a name=d91397e1 class=n-a></a><h2 class=main-title id=d91544>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d91397e1321 class=n-a></a><h2 class=main-title id=d91397e1323>Acknowledgements</h2><p class="" id=d91397e1326>Jeffrey Weitz holds the Canada Research Chair (Tier I) in Thrombosis and the Heart and Stroke Foundation J. Fraser Mustard Chair in Cardiovascular Research at McMaster University.</p></div><div class=back-section><a name=d91397e1330 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d91662>References</h2><div class="section ref-list"><a name=d91397e1330 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d91397e1337 class=n-a></a>Spencer FA, Emery C, Joffe SW, <i> et al.</i>: Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. <i>J Thromb Thrombolysis.</i> 2009; <b>28</b>(4): 4019. <a target=xrefwindow id=d91397e1348 href="http://www.ncbi.nlm.nih.gov/pubmed/19629642">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1351 href="http://dx.doi.org/10.1007/s11239-009-0378-3">Publisher Full Text </a> | <a target=xrefwindow id=d91397e1355 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3248815">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d91397e1364 class=n-a></a>White RH: The epidemiology of venous thromboembolism. <i>Circulation.</i> 2003; <b>107</b>(23 Suppl 1): I48. <a target=xrefwindow id=d91397e1372 href="http://www.ncbi.nlm.nih.gov/pubmed/12814979">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1375 href="http://dx.doi.org/10.1161/01.CIR.0000078468.11849.66">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d91397e1384 class=n-a></a>Silverstein MD, Heit JA, Mohr DN, <i> et al.</i>: Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. <i>Arch Intern Med.</i> 1998; <b>158</b>(6): 58593. <a target=xrefwindow id=d91397e1395 href="http://www.ncbi.nlm.nih.gov/pubmed/9521222">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1398 href="http://dx.doi.org/10.1001/archinte.158.6.585">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d91397e1407 class=n-a></a>Heit JA, Silverstein MD, Mohr DN, <i> et al.</i>: Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. <i>Arch Intern Med.</i> 1999; <b>159</b>(5): 44553. <a target=xrefwindow id=d91397e1418 href="http://www.ncbi.nlm.nih.gov/pubmed/10074952">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1421 href="http://dx.doi.org/10.1001/archinte.159.5.445">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d91397e1430 class=n-a></a>Kearon C: Natural history of venous thromboembolism. <i>Circulation.</i> 2003; <b>107</b>(23 Suppl 1): I2230. <a target=xrefwindow id=d91397e1438 href="http://www.ncbi.nlm.nih.gov/pubmed/12814982">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1441 href="http://dx.doi.org/10.1161/01.CIR.0000078464.82671.78">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d91397e1451 class=n-a></a>Prandoni P, Noventa F, Ghirarduzzi A, <i> et al.</i>: The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. <i>Haematologica.</i> 2007; <b>92</b>(2): 199205. <a target=xrefwindow id=d91397e1462 href="http://www.ncbi.nlm.nih.gov/pubmed/17296569">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1465 href="http://dx.doi.org/10.3324/haematol.10516">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726141242"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1474 class=n-a></a>Kearon C, Akl EA, Ornelas J, <i> et al.</i>: Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest.</i> 2016; <b>149</b>(2): 31552. <a target=xrefwindow id=d91397e1485 href="http://www.ncbi.nlm.nih.gov/pubmed/26867832">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1488 href="http://dx.doi.org/10.1016/j.chest.2015.11.026">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726141242">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1516961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1501 class=n-a></a>Schulman S, Kearon C, Kakkar AK, <i> et al.</i>: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. <i>N Engl J Med.</i> 2009; <b>361</b>(24): 234252. <a target=xrefwindow id=d91397e1512 href="http://www.ncbi.nlm.nih.gov/pubmed/19966341">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1515 href="http://dx.doi.org/10.1056/NEJMoa0906598">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1516961">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d91397e1528 class=n-a></a>Schulman S, Kakkar AK, Goldhaber SZ, <i> et al.</i>: Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. <i>Circulation.</i> 2014; <b>129</b>(7): 76472. <a target=xrefwindow id=d91397e1539 href="http://www.ncbi.nlm.nih.gov/pubmed/24344086">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1542 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004450">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14259964"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1551 class=n-a></a>EINSTEINPE Investigators, Bller HR, Prins MH, <i> et al.</i>: Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. <i>N Engl J Med.</i> 2012; <b>366</b>(14): 128797. <a target=xrefwindow id=d91397e1562 href="http://www.ncbi.nlm.nih.gov/pubmed/22449293">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1565 href="http://dx.doi.org/10.1056/NEJMoa1113572">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14259964">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/9159962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1578 class=n-a></a>EINSTEIN Investigators, Bauersachs R, Berkowitz SD, <i> et al.</i>: Oral rivaroxaban for symptomatic venous thromboembolism. <i>N Engl J Med.</i> 2010; <b>363</b>(26): 2499510. <a target=xrefwindow id=d91397e1589 href="http://www.ncbi.nlm.nih.gov/pubmed/21128814">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1592 href="http://dx.doi.org/10.1056/NEJMoa1007903">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/9159962">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718482057"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1606 class=n-a></a>Agnelli G, Buller HR, Cohen A, <i> et al.</i>: Oral apixaban for the treatment of acute venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>369</b>(9): 799808. <a target=xrefwindow id=d91397e1617 href="http://www.ncbi.nlm.nih.gov/pubmed/23808982">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1620 href="http://dx.doi.org/10.1056/NEJMoa1302507">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718482057">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d91397e1633 class=n-a></a>Hokusai-VTE Investigators, Bller HR, Dcousus H, <i> et al.</i>: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>369</b>(15): 140615. <a target=xrefwindow id=d91397e1644 href="http://www.ncbi.nlm.nih.gov/pubmed/23991658">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1647 href="http://dx.doi.org/10.1056/NEJMoa1306638">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718467623"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1656 class=n-a></a>van Es N, Coppens M, Schulman S, <i> et al.</i>: Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. <i>Blood.</i> 2014; <b>124</b>(12): 196875. <a target=xrefwindow id=d91397e1667 href="http://www.ncbi.nlm.nih.gov/pubmed/24963045">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1670 href="http://dx.doi.org/10.1182/blood-2014-04-571232">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718467623">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717969580"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1683 class=n-a></a>Agnelli G, Buller HR, Cohen A, <i> et al.</i>: Apixaban for extended treatment of venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>368</b>(8): 699708. <a target=xrefwindow id=d91397e1694 href="http://www.ncbi.nlm.nih.gov/pubmed/23216615">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1697 href="http://dx.doi.org/10.1056/NEJMoa1207541">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717969580">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717980888"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1710 class=n-a></a>Schulman S, Kearon C, Kakkar AK, <i> et al.</i>: Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. <i>N Engl J Med.</i> 2013; <b>368</b>(8): 70918. <a target=xrefwindow id=d91397e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/23425163">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1724 href="http://dx.doi.org/10.1056/NEJMoa1113697">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717980888">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725724521"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1737 class=n-a></a>Sindet-Pedersen C, Pallisgaard JL, Olesen JB, <i> et al.</i>: Safety and efficacy of direct oral anticoagulants compared to warfarin for extended treatment of venous thromboembolism -a systematic review and meta-analysis. <i>Thromb Res.</i> 2015; <b>136</b>(4): 7328. <a target=xrefwindow id=d91397e1748 href="http://www.ncbi.nlm.nih.gov/pubmed/26277682">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1751 href="http://dx.doi.org/10.1016/j.thromres.2015.07.022">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725724521">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d91397e1765 class=n-a></a>Weitz JI, Bauersachs R, Beyer-Westendorf J, <i> et al.</i>: Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism. Rationale for and design of the EINSTEIN CHOICE study. <i>Thromb Haemost.</i> 2015; <b>114</b>(3): 64550. <a target=xrefwindow id=d91397e1776 href="http://www.ncbi.nlm.nih.gov/pubmed/25994838">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1779 href="http://dx.doi.org/10.1160/TH15-02-0131">Publisher Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727423286"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1788 class=n-a></a>Weitz JI, Lensing AWA, Prins MH, <i> et al.</i>: Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. <i>N Engl J Med.</i> 2017; <b>376</b>(13): 121122. <a target=xrefwindow id=d91397e1799 href="http://www.ncbi.nlm.nih.gov/pubmed/28316279">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1802 href="http://dx.doi.org/10.1056/NEJMoa1700518">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727423286">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725949590"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1815 class=n-a></a>Marik PE, Cavallazzi R: Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. <i>PLoS One.</i> 2015; <b>10</b>(11): e0143252. <a target=xrefwindow id=d91397e1823 href="http://www.ncbi.nlm.nih.gov/pubmed/26587983">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1826 href="http://dx.doi.org/10.1371/journal.pone.0143252">Publisher Full Text </a> | <a target=xrefwindow id=d91397e1829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4654552">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725949590">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718546183"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1842 class=n-a></a>Simes J, Becattini C, Agnelli G, <i> et al.</i>: Aspirin for the prevention of recurrent venous thromboembolism: the INSPIRE collaboration. <i>Circulation.</i> 2014; <b>130</b>(13): 106271. <a target=xrefwindow id=d91397e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/25156992">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1856 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.114.008828">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718546183">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725320626"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1869 class=n-a></a>Lyman GH, Bohlke K, Khorana AA, <i> et al.</i>: Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. <i>J Clin Oncol.</i> 2015; <b>33</b>(6): 6546. <a target=xrefwindow id=d91397e1880 href="http://www.ncbi.nlm.nih.gov/pubmed/25605844">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1883 href="http://dx.doi.org/10.1200/JCO.2014.59.7351">Publisher Full Text </a> | <a target=xrefwindow id=d91397e1887 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4881372">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725320626">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d91397e1900 class=n-a></a>van Es N, Di Nisio M, Bleker SM, <i> et al.</i>: Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. <i>Thromb Haemost.</i> 2015; <b>114</b>(6): 126876. <a target=xrefwindow id=d91397e1911 href="http://www.ncbi.nlm.nih.gov/pubmed/26271200">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1914 href="http://dx.doi.org/10.1160/TH15-06-0452">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d91397e1924 class=n-a></a>Martin K, Beyer-Westendorf J, Davidson BL, <i> et al.</i>: Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. <i>J Thromb Haemost.</i> 2016; <b>14</b>(6): 130813. <a target=xrefwindow id=d91397e1935 href="http://www.ncbi.nlm.nih.gov/pubmed/27299806">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1938 href="http://dx.doi.org/10.1111/jth.13323">Publisher Full Text </a> | <a target=xrefwindow id=d91397e1942 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4936273">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d91397e1951 class=n-a></a>Prins MH, Lensing AW, Bauersachs R, <i> et al.</i>: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. <i>Thromb J.</i> 2013; <b>11</b>(1): 21. <a target=xrefwindow id=d91397e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/24053656">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1965 href="http://dx.doi.org/10.1186/1477-9560-11-21">Publisher Full Text </a> | <a target=xrefwindow id=d91397e1969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3850944">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1474959"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e1978 class=n-a></a>Connolly SJ, Ezekowitz MD, Yusuf S, <i> et al.</i>: Dabigatran versus warfarin in patients with atrial fibrillation. <i>N Engl J Med.</i> 2009; <b>361</b>(12): 113951. <a target=xrefwindow id=d91397e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/19717844">PubMed Abstract </a> | <a target=xrefwindow id=d91397e1992 href="http://dx.doi.org/10.1056/NEJMoa0905561">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1474959">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d91397e2005 class=n-a></a>Connolly SJ, Wallentin L, Yusuf S: Additional events in the RE-LY trial. <i>N Engl J Med.</i> 2014; <b>371</b>(15): 14645. <a target=xrefwindow id=d91397e2013 href="http://www.ncbi.nlm.nih.gov/pubmed/25251519">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2016 href="http://dx.doi.org/10.1056/NEJMc1407908">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718444775"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e2025 class=n-a></a>Douxfils J, Buckinx F, Mullier F, <i> et al.</i>: Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. <i>J Am Heart Assoc.</i> 2014; <b>3</b>(3): e000515. <a target=xrefwindow id=d91397e2036 href="http://www.ncbi.nlm.nih.gov/pubmed/24906369">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2039 href="http://dx.doi.org/10.1161/JAHA.113.000515">Publisher Full Text </a> | <a target=xrefwindow id=d91397e2043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4309041">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718444775">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718201417"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e2056 class=n-a></a>Ruff CT, Giugliano RP, Braunwald E, <i> et al.</i>: Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. <i>Lancet.</i> 2014; <b>383</b>(9921): 95562. <a target=xrefwindow id=d91397e2067 href="http://www.ncbi.nlm.nih.gov/pubmed/24315724">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2070 href="http://dx.doi.org/10.1016/S0140-6736(13)62343-0">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718201417">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725830213"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e2084 class=n-a></a>Caldeira D, Barra M, Ferreira A, <i> et al.</i>: Systematic review with meta-analysis: the risk of major gastrointestinal bleeding with non-vitamin K antagonist oral anticoagulants. <i>Aliment Pharmacol Ther.</i> 2015; <b>42</b>(1112): 123949. <a target=xrefwindow id=d91397e2095 href="http://www.ncbi.nlm.nih.gov/pubmed/26434935">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2098 href="http://dx.doi.org/10.1111/apt.13412">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725830213">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725057600"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e2111 class=n-a></a>Graham DJ, Reichman ME, Wernecke M, <i> et al.</i>: Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. <i>Circulation.</i> 2015; <b>131</b>(2): 15764. <a target=xrefwindow id=d91397e2122 href="http://www.ncbi.nlm.nih.gov/pubmed/25359164">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2125 href="http://dx.doi.org/10.1161/CIRCULATIONAHA.114.012061">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725057600">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d91397e2138 class=n-a></a>Baron TH, Kamath PS, McBane RD: Management of antithrombotic therapy in patients undergoing invasive procedures. <i>N Engl J Med.</i> 2013; <b>368</b>(22): 211324. <a target=xrefwindow id=d91397e2146 href="http://www.ncbi.nlm.nih.gov/pubmed/23718166">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2149 href="http://dx.doi.org/10.1056/NEJMra1206531">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d91397e2158 class=n-a></a>Weitz JI, Pollack CV Jr: Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants. <i>Thromb Haemost.</i> 2015; <b>114</b>(6): 111326. <a target=xrefwindow id=d91397e2166 href="http://www.ncbi.nlm.nih.gov/pubmed/26155974">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2169 href="http://dx.doi.org/10.1160/TH15-03-0222">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725514035"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d91397e2178 class=n-a></a>Pollack CV Jr: Coagulation assessment with the new generation of oral anticoagulants. <i>Emerg Med J.</i> 2016; <b>33</b>(6): 42330. <a target=xrefwindow id=d91397e2186 href="http://www.ncbi.nlm.nih.gov/pubmed/25987596">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2189 href="http://dx.doi.org/10.1136/emermed-2015-204891">Publisher Full Text </a> | <a target=xrefwindow id=d91397e2192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4893109">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725514035">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d91397e2205 class=n-a></a>Levy JH, Ageno W, Chan NC, <i> et al.</i>: When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. <i>J Thromb Haemost.</i> 2016; <b>14</b>(3): 6237. <a target=xrefwindow id=d91397e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/26911798">PubMed Abstract </a> | <a target=xrefwindow id=d91397e2219 href="http://dx.doi.org/10.1111/jth.13227">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-985.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-985.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Medicine, McMaster University, Hamilton, Ontario, Canada<br/> <sup>2</sup> Department of Surgery, McMaster University, Hamilton, Ontario, Canada<br/> <sup>3</sup> Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada<br/> <sup>4</sup> Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-985/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 23 Jun 2017, 6:985 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11174.1">https://doi.org/10.12688/f1000research.11174.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden">  2017 Weitz JI <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12057 data-id=11174 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11174.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-985/v1/pdf?article_uuid=ec5be32c-00a3-4c41-bb60-a40c293e04f9" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11174.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Weitz JI, Jaffer IH and Fredenburgh JC. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):985 (<a href="https://doi.org/10.12688/f1000research.11174.1" target=_blank>https://doi.org/10.12688/f1000research.11174.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11174 id=mobile-track-article-signin-11174 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11174?target=/articles/6-985.html"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12057 /> <input name=articleId type=hidden value=11174 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Esteban G&aacute;ndara</strong>, Department of Internal Medicine, Hospital Privado de Comunidad, Mar del Plata, Argentina </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Menno V. Huisman</strong>, Department of Thrombosis and Haemostasis, Leiden University Medical Center, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Menno V Huisman has previously collaborated with the author, Jeffrey Weitz, on the RE-VERSE AD trial (NCT02104947). (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 23 Jun 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-985.html&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-985.html&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=23589-23758></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=5264-23757></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-985/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>23 Jun 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Esteban G&aacute;ndara</strong>, Department of Internal Medicine, Hospital Privado de Comunidad, Mar del Plata, Argentina </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Menno V. Huisman</strong>, Department of Thrombosis and Haemostasis, Leiden University Medical Center, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Menno V Huisman has previously collaborated with the author, Jeffrey Weitz, on the RE-VERSE AD trial (NCT02104947). </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-985.html&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-985/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the treatment of venous...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-985/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-985/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-985/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Weitz JI et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-985/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-985",
            templates : {
                twitter : "Recent advances in the treatment of venous thromboembolism in.... Weitz JI et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-985/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11174/12057")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12057");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "23757": 0,
                           "23758": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "5e4859a4-8667-4699-a285-b8ba1d8e35ed";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-985.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-985.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-985.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-985.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-985.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>